Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01858831 | Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension | PHASE1 | COMPLETED | 30 | — | — | Apr 1, 2012 | May 1, 2012 | Mar 22, 2017 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| Atovaquone/proguanil HCL | EXPERIMENTAL | Atovaquone/proguanil HCL |
| Atovaquone 750 mg | ACTIVE_COMPARATOR | Atovaquone 750 mg |
| Atovaquone 1500 mg | ACTIVE_COMPARATOR | Atovaquone 1500 mg |
| Name | Type | Description |
|---|---|---|
| Atovaquone/proguanil HCL | DRUG | Atovaquone/proguanil HCL |
| Atovaquone | DRUG | Atovaquone |
Inclusion Criteria: * Healthy as defined as being free from clinically significant illness or disease as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital sign, laboratory tests and ECG. * Japanese healthy mal...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 4 | PHASE3 | Tafenoquine, Primaquine, Chloroquine, GSK3772701, RTS,S/AS01E vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |